Genesis originated from Stanford University’s Vijay Pande lab, where foundational research in graph machine learning laid the groundwork for the company’s innovative approach.
Since its inception in 2019, Genesis has secured significant funding from prominent investors, including Rock Springs Capital, T. Rowe Price, Menlo Ventures, Radical Ventures, Andreessen Horowitz, Nventures (NVIDIA’s venture capital arm), and others. NVIDIA’s recent investment is focused on accelerating the development of GEMS, particularly optimising computational methods like equivariant neural networks for analysing complex 3D molecular structures.
The company has also formed key collaborations with Genentech, Eli Lilly, and, most recently, Gilead Sciences.
Propagator Ventures supports Genesis Therapeutics in its mission to harness AI for the development of breakthrough therapies targeting diseases with high unmet medical needs.